Blog
DEA and FDA clear Epidiolex: Where do we go from here?
On September 27, 2018, the Drug Enforcement Agency (DEA) made a remarkable move. The agency placed a cannabidiol (CBD) containing product, Epidiolex, into Schedule V (classified as having low potential for abuse) so that it could be manufactured in t…